Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBT: 2017-2025

Historic EBT for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$130.1 million.

  • Crinetics Pharmaceuticals' EBT fell 69.33% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 54.83%. This contributed to the annual value of -$297.4 million for FY2024, which is 42.19% down from last year.
  • Crinetics Pharmaceuticals' EBT amounted to -$130.1 million in Q3 2025, which was down 12.48% from -$115.7 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year EBT high stood at -$22.9 million for Q1 2021, and its period low was -$130.1 million during Q3 2025.
  • For the 3-year period, Crinetics Pharmaceuticals' EBT averaged around -$77.2 million, with its median value being -$74.0 million (2024).
  • Data for Crinetics Pharmaceuticals' EBT shows a maximum YoY tumbled of 75.14% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' EBT stood at -$26.1 million in 2021, then crashed by 75.14% to -$45.7 million in 2022, then fell by 22.53% to -$55.9 million in 2023, then slumped by 43.69% to -$80.4 million in 2024, then tumbled by 69.33% to -$130.1 million in 2025.
  • Its EBT stands at -$130.1 million for Q3 2025, versus -$115.7 million for Q2 2025 and -$96.6 million for Q1 2025.